Navigation Links
FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
Date:11/24/2009

WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ -- Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl extended release) tablets for the treatment of moderate to severe Alzheimer's disease (AD). This new higher dose formulation contains 23 mg of donepezil HCl in an extended release, matrix-type tablet with a delivery system that allows for gradual release of the drug. The NDA is based on a head-to-head clinical study comparing the 23 mg Aricept extended release tablet to the currently marketed once daily 10 mg Aricept® (donepezil HCl) immediate release tablet. More than 1400 patients with moderate to severe Alzheimer's disease were enrolled in this global study.

Acceptance of the NDA indicates that the FDA has found the company's submission to be sufficiently complete to review. Eisai and Pfizer believe this new formulation will potentially provide physicians, patients and their families with another option for the management of Alzheimer's disease.

About Aricept® (donepezil HCl) tablet

Aricept is the first and only prescription medication approved by the FDA for the treatment of all stages of AD -- mild, moderate and severe dementia of the Alzheimer's type. This indication is supported by evidence-based medicine, with numerous well-controlled clinical studies of AD in all stages and multiple settings among thousands of patients, demonstrating that Aricept improves cognition and slows the decline of overall function. Aricept is currently available in 5 mg and 10 mg immediate release tablets, dosed once daily. It is co-promoted in the United States by Eisai Inc. and Pfizer Inc.

Aricept is well tolerated but may not be for everyone. People at risk for stomach ulcers or who take certain other medicines should tell t
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
5. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
11. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Rico , May 17, 2013  Serving a region ... Puerto Rico , Caribbean Imaging and Radiation Therapy (CIRT, ... radiation therapy capabilities with the acquisition of an Elekta Versa ... . Versa HD offers clinicians the versatility to deliver conventional ... body, while also enabling treatment of highly complex cancers that ...
(Date:5/17/2013)... PARIS , May 17, 2013  Sanofi (EURONEXT: ... the pivotal study, JAKARTA , examining ... its primary endpoint in both dose groups. The primary ... of spleen volume. Consistent with data reported in previous ... nausea and vomiting. Full results will be presented at ...
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
Breaking Medicine Technology:Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... , NEW YORK , July 20 ... the Susquehanna International Group of Companies (SIG), announced today that ... Senior Analyst covering the Specialty Pharmaceuticals sector. Mr. Nachman, whose ... Labs , King Pharmaceuticals, Shire Pharmaceuticals and Warner Chilcott ...
... July 20 Medical Device Consultants, Inc. ... (CRO) serving the medical device and diagnostics industry, today ... Services Ltd (CDSS), a clinical services and CRO based ... clients access to the best of both organizations, core ...
Cached Medicine Technology:Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector 2Susquehanna Financial Group Hires Gary Nachman as Senior Analyst to Cover the Specialty Pharmaceuticals Sector 3Medical Device Consultants, Inc. and Clinical Development & Support Services Ltd Announce Strategic Partnership 2Medical Device Consultants, Inc. and Clinical Development & Support Services Ltd Announce Strategic Partnership 3
(Date:5/19/2013)... California (PRWEB) May 19, 2013 According to ... Body Firmers” many people are self-conscious about the appearance of ... an option when diet and exercise fail to tone and ... may appeal to those looking to get the firmest ... is an effective mini-overview,” says Dr. Simon Ourian, Medical Director ...
(Date:5/19/2013)... St. Louis, MO (PRWEB) May 19, 2013 ... Member Conference, May 19-22, 2013, at the Walt Disney ... the latest trends in supply chain innovation, care delivery ... a much different dynamic in all healthcare markets, ... necessary part of the conversation,” said Todd Ebert, Amerinet ...
(Date:5/19/2013)... Omaha, Nebraska is a city of diversity, economic growth ... the lowest unemployment rates in the country. Forbes Magazine distinguished ... Business and Careers and it consistently scores high on many ... in the nation and is a strong business leader thanks ... Editions TV are pleased to announce air dates ...
(Date:5/19/2013)... in Minnesota have a great option to get in shape ... Fat Loss Formula. The best part is people can ... The product sells for $135 dollars and is an immediate ... http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is almost here. People may ... the 28 Day Fat Loss Formula they will be happy ...
(Date:5/19/2013)... 2013 In partnership with the medical practice ... the launch of an SEO website for dentists. The purpose ... in Google. , http://www.e-dentists.com/ , A perk to ... service until they see results. Dentists can request the keywords ... run by JD Media Surge, LLC rank high for competitive ...
Breaking Medicine News(10 mins):Health News:Body Firming – The Hottest Treatments Available 2Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Editions TV Announces May Air Dates for Omaha, Nebraska 2Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2
... According to a new federal report, in spite of the ... several new programs to overcome it//, the efficacy of these ... efforts need national leadership, according to the report, Progress in ... Institute of Medicine. This report was released yesterday. ...
... revealed that there is a “crisis” over lack of donors at ... clinics being totally out of stock//, women and couples wanting to ... the highest number of donors was 459. Ever since, the number ... law was passed that gave kids the right to know the ...
... week the distribution of a drug to help fight an ... is being affected by an extremely virulent strain of tuberculosis, ... the country. The health officials have now promised that they ... week to help fight the disease. The officials but also ...
... for an extensive study for the evaluation of the possible ... stents. // ,Stents are widely used heart devices ... had essentially eliminated short-term restenosis as a complication of coronary ... cloud for possible late-term risks. Reports indicate that almost 6 ...
... unique way to curb binge drinking, researchers say parents should allow ... youngsters // to drink at parties and at home may be ... ,Professor Mark Bellis, the author of the report said that children ... and allowed to drink with them were sensible in their approach ...
... a safe way to monitor the fate of transplanted ... issue of the journal Diabetes. // Researchers from the ... (MGH) said that they were able to track transplanted ... human transplants. ,"Clinical trials and animal studies ...
Cached Medicine News:Health News:Slow Fight Against Childhood Obesity 2Health News:Slow Fight Against Childhood Obesity 3Health News:Shortage of donors at sperm bank clinics 2Health News:South Africa To Make Available Two New Drugs To Fight The TB Outbreak 2Health News:MRI Can Monitor Transplanted Islets 2
... (Low Melt), A low temperature agarose ... temperature , Optimal for in-gel restriction digestion/ligation ... a very manageable clear gel that provides ... at approximately 65°C and remains fluid at ...
... Molecular Biology Grade, is used ... nucleic acids. It can be ... from 0.2 to 40 kb., ... is tested and certified to ...
... UltraPure™ Agarose 1000 is specifically formulated for ... PCR fragments <1000 bp. This standard melting ... as little as 10 bp difference in ... a strong gel structure for better handling ...
Agarose IEF is suitable for isoelectric focusing of large molecules and is the gel of choice for many IEF applications and immunochemical detection methods....
Medicine Products: